19th January 2021 Product update: rapidvirology staff writer
New Cell Culture Portfolio for Fight Against COVID-19
Captivate Bio has launched a portfolio of cell culture tools to assist in the fight against COVID-19 and other emerging diseases and help address the gaps exposed by supply chain issues and delays in cell culture media manufacturing in the United States.
Captivate Bio initiated operations in June 2020 and has achieved several critical milestones, including the first product shipment to customers in just 2 short months while inking key scientific collaborations that will help fuel its aggressive growth strategy.
Founded by and women-led, the management team has extensive experience in media manufacturing, supply chain and commercialization; the company is already transacting and rapidly generating revenue.
The Captivate Bio team’s experience in sourcing raw materials, commercialization, and supply chain know-how have allowed them to successfully launch a portfolio of research products.
The company holds memberships with Mass Bio, BioCT, and plans for operational expansions are currently underway.
Date Published: 19th January 2021
Source article link: View
Note: This content has been edited by a rapidvirology.com staff writer for style and content.
Manufacturer Confirms No Impact on
Fast Analysis of SARS-CoV-2 Mutations